Glassman Wealth Services I Mab Transaction History

Glassman Wealth Services

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 04, 2022	SELL	$8.27 - $18.43 $1,513 - $3,372	-183 Reduced 57.19%	137 $2,000
Q1 2022 Apr 14, 2022	BUY	$12.54 - $46.93 $2,445 - $9,151	195 Added 156.0%	320 $5,000
Q4 2021 Feb 14, 2022	SELL	$45.28 - $74.5 $2,037 - $3,352	-45 Reduced 26.47%	125 $6,000
Q3 2021 Nov 10, 2021	SELL	$57.18 - $84.43 $171 - $253	-3 Reduced 1.73%	170 $12,000
Q2 2021 Aug 04, 2021	BUY	$47.86 - $83.95 $8,279 - $14,523	173 New	173 $15,000

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $78.9M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Glassman Wealth Services, based on Form 13F filings with the SEC.

Stay updated on Glassman Wealth Services with notifications on news.